SCHEMBL5358237

SCHEMBL5358237

Cc1ccc(C=C2C(=O)Nc3ccc(OC(=O)CO)cc32)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 2/20 0.44
TLK2 Q86UE8 7/20 0.43
RET P07949 5/20 0.43
EGFR P00533 1/20 0.42
PDPK1 O15530 2/20 0.41
CDK2 P24941 3/20 0.40
CCNE1 P24864 2/20 0.40
MDM2 Q00987 1/20 0.40
CDK1 P06493 2/20 0.40
MAPK1 P28482 2/20 0.40
KDR P35968 2/20 0.40
GSK3A P49840 2/20 0.40
GSK3B P49841 2/20 0.40
CDK7 P50613 2/20 0.40
CDK9 P50750 2/20 0.40
CDK5 Q00535 2/20 0.40
PLK4 O00444 1/20 0.40
CHEK1 O14757 1/20 0.40
AURKA O14965 1/20 0.40
JAK2 O60674 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5376987 0.81 RET (0.44) LRRK2TLK2RETEGFRPDPK1
SCHEMBL5358502 0.81 LRRK2 (0.42) LRRK2TLK2RETEGFRPDPK1
SCHEMBL5364695 0.80 RET (0.44) LRRK2TLK2RETPDPK1CDK2
SCHEMBL5359077 0.80 EGFR (0.47) LRRK2EGFRPDPK1MAPK1KDR
SCHEMBL5368750 0.79 RET (0.71) TLK2RETPDPK1MAPK1KDR
SCHEMBL14519109 0.78 TLK2 (0.57) TLK2PDPK1CDK2CDK1KDR
SCHEMBL5365829 0.77 PDPK1 (0.48) TLK2RETEGFRPDPK1CDK1
SCHEMBL5368073 0.77 PDPK1 (0.61) TLK2PDPK1CDK1GSK3BAURKA
SCHEMBL5369374 0.76 TLK2 (0.71) TLK2RETPDPK1CDK1KDR
SCHEMBL6001532 0.76 LRRK2 (0.58) LRRK2RETEGFRMDM2RPS6KA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK LRRK2 289/4885TLK2 48/4885RET 283/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.